Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
Status:
Recruiting
Trial end date:
2022-12-05
Target enrollment:
Participant gender:
Summary
The study is designed to demonstrate the safety and efficacy of two dose concentrations of
SAF312 eye drops (dose 1 and dose 2) in subjects with CICP persisting at least for 4 months
after refractive surgery and chronicity confirmed during the observational period. The study
will also determine the optimal dose to carry forward for further development.